-
Product Insights
Meibomian Blepharitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Meibomian Blepharitis - Drugs In Development, 2023’, provides an overview of the Meibomian Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meibomian Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Blepharitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Blepharitis - Drugs In Development, 2023’, provides an overview of the Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Sinusitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sinusitis - Drugs In Development, 2023’, provides an overview of the Sinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Rhinosinusitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhinosinusitis - Drugs In Development, 2023’, provides an overview of the Rhinosinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhinosinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertrophic Cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, the sensation of rapid, fluttering, or pounding heartbeats, and heart murmur. HCM usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners. The HCM pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete...
-
Product Insights
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. The Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development market research report provides an in-depth analysis of Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor...